These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 6980706

  • 1. Clinical pharmacology of 9-beta-D-arabinofuranosyladenine in combination with 2'-deoxycoformycin.
    Agarwal RP, Blatt J, Miser J, Sallan S, Lipton JM, Reaman GH, Holcenberg J, Poplack DG.
    Cancer Res; 1982 Sep; 42(9):3884-6. PubMed ID: 6980706
    [Abstract] [Full Text] [Related]

  • 2. S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine.
    Hershfield MS, Kredich NM, Koller CA, Mitchell BS, Kurtzberg J, Kinney TR, Falletta JM.
    Cancer Res; 1983 Jul; 43(7):3451-8. PubMed ID: 6601986
    [Abstract] [Full Text] [Related]

  • 3. 2'-deoxycoformycin (DCF) and 9-beta-D-arabinofuranosyladenine (Ara-A) in the treatment of refractory acute myelocytic leukemia.
    Gray DP, Grever MR, Siaw MF, Coleman MS, Balcerzak SP.
    Cancer Treat Rep; 1982 Feb; 66(2):253-7. PubMed ID: 6976833
    [Abstract] [Full Text] [Related]

  • 4. Modulation of 9-beta-D-arabinofuranosyladenine 5'-triphosphate and deoxyadenosine triphosphate in leukemic cells by 2'-deoxycoformycin during therapy with 9-beta-D-arabinofuranosyladenine.
    Plunkett W, Benjamin RS, Keating MJ, Freireich EJ.
    Cancer Res; 1982 May; 42(5):2092-6. PubMed ID: 6175407
    [Abstract] [Full Text] [Related]

  • 5. Levels of 2'-deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemia.
    Venner PM, Glazer RI, Blatt J, Sallan S, Rivera G, Holcenberg JS, Lipton J, Murphy SB, Poplack DG.
    Cancer Res; 1981 Nov; 41(11 Pt 1):4508-11. PubMed ID: 6975654
    [Abstract] [Full Text] [Related]

  • 6. Therapy with 9-beta-D-arabinofuranosyladenine (ARA-A) and 2'-deoxycoformycin increases the ARA-A content of ocular tissues.
    O'Brien WJ.
    Curr Eye Res; 1986 Aug; 5(8):595-9. PubMed ID: 3489583
    [Abstract] [Full Text] [Related]

  • 7. Phase I study of 2'-deoxycoformycin in acute lymphoblastic leukemia.
    Poplack DG, Sallan SE, Rivera G, Holcenberg J, Murphy SB, Blatt J, Lipton JM, Venner P, Glaubiger DL, Ungerleider R, Johns D.
    Cancer Res; 1981 Sep; 41(9 Pt 1):3343-6. PubMed ID: 6973390
    [Abstract] [Full Text] [Related]

  • 8. Potentiation of growth-inhibitory activity of 9-beta-D-arabinofuranosyladenine by 2'-deoxycoformycin in human cultured cell lines derived from leukemias and lymphomas.
    Kuroki Y, Shimoyama M, Inaba S, Hirose M.
    Jpn J Cancer Res; 1989 May; 80(5):482-9. PubMed ID: 2502523
    [Abstract] [Full Text] [Related]

  • 9. Cerebrospinal fluid levels of 2'-deoxycoformycin after systemic administration in monkeys.
    Blatt J, Venner PM, Riccardi R, Cohen LF, Gangji D, Glazer RI, Poplack DG.
    J Natl Cancer Inst; 1982 Mar; 68(3):391-3. PubMed ID: 6977672
    [Abstract] [Full Text] [Related]

  • 10. Clinical pharmacology of arabinofuranosyladenine in combination with deoxycoformycin.
    Major PP, Agarwal RP, Kufe DW.
    Cancer Chemother Pharmacol; 1983 Mar; 10(2):125-8. PubMed ID: 6600984
    [No Abstract] [Full Text] [Related]

  • 11. Specificity of 2'-deoxycoformycin inhibition of adenosine metabolism in intact human skin fibroblasts.
    Holland MJ.
    Res Commun Chem Pathol Pharmacol; 1986 Mar; 51(3):311-24. PubMed ID: 3486439
    [Abstract] [Full Text] [Related]

  • 12. 2'-deoxycoformycin. A new anticancer agent.
    Poster DS, Penta JS, Bruno S, Macdonald JS.
    Cancer Clin Trials; 1981 Mar; 4(2):209-13. PubMed ID: 7018725
    [Abstract] [Full Text] [Related]

  • 13. Induction of complete remission in T-cell acute lymphoblastic leukemia with deoxycoformycin (dcf) and 9-beta-D-arabinofuranosyladenine (ara-A).
    Yu AL, Mendelsohn J, Matsumoto SS.
    Adv Exp Med Biol; 1986 Mar; 195 Pt A():491-6. PubMed ID: 3487920
    [No Abstract] [Full Text] [Related]

  • 14. [Problems of antineoplastic effects by PLDR (potential lethal damage repair) inhibitor--pharmacokinetics].
    Sougawa M, Akagi K, Yoshii G, Tanaka Y.
    Gan No Rinsho; 1984 Nov; 30(14):1787-92. PubMed ID: 6334757
    [Abstract] [Full Text] [Related]

  • 15. Correlation of cytotoxicity with total intracellular exposure to 9-beta-D-arabinofuranosyladenine 5'-triphosphate.
    Shewach DS, Plunkett W.
    Cancer Res; 1982 Sep; 42(9):3637-41. PubMed ID: 6179604
    [Abstract] [Full Text] [Related]

  • 16. Effects of deoxycoformycin in mice. II. Differences between the drug sensitivities and purine metabolizing enzymes of transplantable lymphomas of varying immunologic phenotypes.
    Ratech H, Kim J, Asofsky R, Thorbecke GJ, Hirschhorn R.
    J Immunol; 1984 Jun; 132(6):3077-84. PubMed ID: 6202772
    [Abstract] [Full Text] [Related]

  • 17. Enhancement of 9-beta-d-arabinofuranosyladenine cytotoxicity to mouse leukemia L1210 in vitro by 2'-deoxycoformycin.
    Cass CE, Au-Yeung TH.
    Cancer Res; 1976 Apr; 36(4):1486-91. PubMed ID: 944095
    [Abstract] [Full Text] [Related]

  • 18. Effects of 2'-deoxycoformycin on the metabolism of purines and the survival of malignant cells in a patient with T-cell leukemia.
    Yu AL, Bakay B, Kung FH, Nyhan WL.
    Cancer Res; 1981 Jul; 41(7):2677-82. PubMed ID: 6972800
    [Abstract] [Full Text] [Related]

  • 19. Relationship of 5'-nucleotidase activity and antileukemic effect in 2'-deoxycoformycin therapy.
    Wortmann RL, Holcenberg J, Poplack DG.
    Cancer Treat Rep; 1982 Feb; 66(2):387-90. PubMed ID: 6275991
    [No Abstract] [Full Text] [Related]

  • 20. Resistance to 9-beta-D-arabinofuranosyladenine in cultured leukemia L 1210 cells.
    Cass CE, Selner M, Phillips JR.
    Cancer Res; 1983 Oct; 43(10):4791-8. PubMed ID: 6603904
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.